Peter Powchik - Regeneron Pharmaceuticals Senior Vice President - Clinical Development

REGN -- USA Stock  

Fiscal Quarter End: December 31, 2019  

  President
Dr. Peter Powchik, M.D., is Senior Vice President Clinical Development of the Company. Dr. Powchik was employed at several pharmaceutical companies, serving as Senior Vice President and Chief Medical Officer of Chugai Pharma USA, a position he held from May 2005 until October 2006. From April 2001 until May 2005, he held various senior clinical development positions at Novartis Pharmaceuticals Corporationrationration, most recently as Vice President, US Clinical Development and Medical Affairs. Dr. Powchik held various clinical development positions with Sepracor Inc. and Pfizer Inc. from October 1996 to April 2001. Dr. Powchik received his M.D. from New York University School of Medicine.
Age: 59  President Since 2006      
914 847-7000  www.regeneron.com

Peter Powchik Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 11.38 % which means that it generated profit of $11.38 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 23.34 % meaning that it created $23.34 on every $100 dollars invested by stockholders.
The company currently holds 738 M in liabilities with Debt to Equity (D/E) ratio of 7.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals has Current Ratio of 3.95 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 7674 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 7,674 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
George Sing, Independent Director
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Stock Performance Indicators

Did you try this?

Run Companies Directory Now

   

Companies Directory

Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
All  Next Launch Module

Currently Active Assets on Macroaxis

V   
Purchased few shares of
1 hour ago
Traded for 181.89
TWTR   
Purchased over 100 shares of
1 hour ago
Traded for 30.04
VMW   
Purchased over 20 shares of
1 hour ago
Traded for 148.32
CRM   
Purchased few shares of
1 hour ago
Traded for 158.22
MSFT   
Purchased a lot of shares of
1 hour ago
Traded for 149.93
Additionally take a look at Your Equity Center. Please also try Aroon Oscillator module to analyze current equity momentum using aroon oscillator and other momentum ratios.
Search macroaxis.com